Behandling af neuroendokrine gastrointestinale tumorer

Carsten Palnaes Hansen, Seppo Langer, Susanne Frevert, Jann Mortensen, Andreas Kjær, Ulrich Knigge

    Abstract

    The prognosis of neuroendocrine tumours of the gastrointestinal tract and pancreas is difficult to estimate due to their heterogeneous nature. Survival without dissemination may reach 90%, while metastases reduce the 5-year survival to less than 50%. Radical surgery offers the only possibility of cure. Palliative therapy includes surgery and intra-arterial embolization of hepatic metastases, chemotherapy, biotherapy with interferon-alpha and radionuclear treatment. Tumour-targeted therapy with tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors or monoclonal antibodies are under investigation in phase-III studies.
    Bidragets oversatte titel[Treatment of neuroendocrine tumours of the gastrointestinal tract]
    OriginalsprogDansk
    TidsskriftUgeskrift for Laeger
    Vol/bind172
    Udgave nummer43
    Sider (fra-til)2942-5
    Antal sider4
    ISSN0041-5782
    StatusUdgivet - 25 okt. 2010

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Behandling af neuroendokrine gastrointestinale tumorer'. Sammen danner de et unikt fingeraftryk.

    Citationsformater